title: [Assessment of transforming growth factor-beta1 in serum of children with idiopathic nephrotic syndrome depending on the way of treatment].
abstract: The concentration of transforming growth factor-beta 1 (TGF-beta 1) in serum was performed by immunoenzymatic method in serum of children with nephrotic syndrome in following groups: group I--9 children (5-15 years) with focal segmental glomerulosclerosis (FSG), before Cyclosporine A treatment (CyA) (examination A) and after 3-6 months of Cyclosporine A treatment during remission (examination B), group II--13 children (5-14 years) with minimal change nephrotic syndrome (MCNS) during relapse (examination A) and after 7-20 days of prednisone (Encorton) treatment in dose 60 mg/m2, without the proteinuria (examination B), group III--15 healthy children (5-15 years). The aim of the work was to demonstrate any differences in concentration of TGF-beta 1 in serum of examined children and to show the influence of prednisone and Cyclosporine A on the concentration of TGF-beta 1. The results showed that before treatment increased concentration of TGF-beta 1 was shown only in children with MCSN (p < 0.05) and it was reverse proportional to albuminemia. However in children without proteinuria (B), the concentration of cytokines decreased in children with MCSN and increased in children with FSG treated with Cyclosporine A.
  
  
  CONCLUSIONS
  The concentration of TGF-beta 1 in serum increases in children with nephrotic syndrome during gross proteinuria and hypoalbuminemia and after Cyclosporine A treatment.
authors.affiliation: I Klinika Chorób Dzieci AM w Białymstoku.
authors.forename: Anna
authors.initials: A
authors.lastname: Wasilewska
authors.forename: Walentyna
authors.initials: W
authors.lastname: Zoch-Zwierz
authors.forename: Barbara
authors.initials: B
authors.lastname: Tomaszewska
authors.forename: Ryszard
authors.initials: R
authors.lastname: Wierciński
authors.forename: Wiesława
authors.initials: W
authors.lastname: Winiecka
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Smółko
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Porowski
authors.forename: Alicja
authors.initials: A
authors.lastname: Koput
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Janicka
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D009404:Nephrotic Syndrome / Q000097:blood* / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000097:blood*; D053773:Transforming Growth Factor beta1
chemical_list: D000893:Anti-Inflammatory Agents; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D011241:Prednisone